Evidence map›Paper›PMID 31744319›Full record

Trial reportCephalalgia : an international journal of headache2020

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.

Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li Shen Loo, Mika Komori, Joshua Tobin

2 registry-linked trialsAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cephalalgia : an international journal of headache, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02439320 phase3completednot on this map

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

TypeinterventionalSponsorEli Lilly and CompanyRan2015 to 2016Enrolled2,231ConditionsAcute MigraineArmsLasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses)
NCT02605174 phase3completednot on this map

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

TypeinterventionalSponsorEli Lilly and CompanyRan2016 to 2017Enrolled3,005ConditionsMigraine With or Without AuraArmsLasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Short-term efficacy and safety of lasmiditan, a novel 5-HTThe journal of headache and pain · 2020
    Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  15. The 5-HTNature reviews. Neurology · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Novel Analgesics with Peripheral Targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  20. Lasmiditan mechanism of action - review of a selective 5-HTThe journal of headache and pain · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kerry KnievelBarrow Neurological Institute, Phoenix, AZ, USA.
Andrew S BuchananEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Louise LombardEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Simin BayganiEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Joel RaskinEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
John H KregeEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Li Shen LooEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Mika KomoriEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Joshua Tobin21st Century Neurology, Xenoscience, Phoenix, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated analyses evaluated the efficacy of lasmiditan in patients who reported a good or insufficient response to triptans and in those who were triptan naïve.

methodsSubgroups of patients reporting an overall response of "good" or "poor/none" to the most recent use of a triptan at baseline (defined as good or insufficient responders, respectively) and a triptan-naïve subpopulation were derived from combined study participants randomized to receive lasmiditan 50 mg (SPARTAN only), 100 mg or 200 mg, or placebo, as the first dose. Outcomes including headache pain-freedom, most bothersome symptom-freedom, and headache pain relief 2 hours post-first dose of lasmiditan were compared with placebo. Treatment-by-subgroup analyses additionally investigated whether therapeutic benefit varied according to prior triptan response (good or insufficient).

resultsRegardless of triptan response, lasmiditan showed higher efficacy than placebo (most comparisons were statistically significant). Treatment-by-subgroup analyses found that the benefit over placebo of lasmiditan did not vary significantly between patients with a good response and those with an insufficient response to triptans. Lasmiditan also showed higher efficacy than placebo in triptan-naïve patients.

conclusionsLasmiditan demonstrated comparable efficacy in patients who reported a good or insufficient response to prior triptan use. Lasmiditan also showed efficacy in those who were triptan naïve. Lasmiditan may be a useful therapeutic option for patients with migraine.

trial registrationSAMURAI (NCT02439320); SPARTAN (NCT02605174).

Indexed as

AdultBenzamidesDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedMigraine DisordersPiperidinesPyridinesSerotonin Receptor AgonistsTreatment OutcomeTryptaminesBenzamideslasmiditanPiperidinesPyridinesSerotonin Receptor AgonistsTryptaminesacute therapyditanefficacylasmiditanMigrainetolerabilitytriptans

Identifiers

PMID31744319
PMCPMC6950889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.